Vetropack Holding AG (SWX: VETN)

Intro

Vetropack is a Swiss manufacturer of glass packaging – bottles and jars primarily for the food and beverage industries. Founded in 1911 and headquartered in Bülach, it operates glassworks across Austria, the Czech Republic, Slovakia, Croatia, Italy, Moldova and Ukraine.

The company remains firmly in family hands. The Cornaz family controls 72% of the voting rights, a structure that has kept the business long-term oriented – for better and, some would argue during the current downturn, for worse.

What makes Vetropack interesting now is that almost everything that could go wrong for a glass maker has gone wrong at once, and the shares have been punished accordingly.

Valuation

The shares trade around CHF 18.74, giving a market capitalisation of roughly CHF 370 million. On trailing earnings the stock looks expensive – 2025 was barely profitable – but trailing earnings are exactly the trap here.

Two things are depressing the reported numbers. First, a wave of one-off charges: closure costs and asset write-downs in 2025. Second, a brutal demand and pricing environment across European glass, where market overcapacity, adverse price and product mix, and a high fixed-cost base have severely compressed margins. Group production volumes were broadly stable in 2025, so the pressure was not simply caused by falling production volumes.

Strip out the noise and the adjusted operating result was CHF 37.5 million in 2025, down from CHF 58.6 million – depressed, but a long way from the near-zero bottom line. Cash flow from operating activities was still CHF 107 million. This is a company earning far below its own normalised potential, not a broken one.

What's next?

The risks are real. European glass demand remains soft and management has cut the dividend sharply – to CHF 0.50 per share from CHF 1.00 – which tells you how cautious the board is. Cheap can stay cheap while the cycle grinds on. Management also expects 2026 revenue to remain below the 2025 level, despite anticipating stable volumes and a modest improvement in the operating margin.

But the self-help is visible. The cost base is being reset for a smaller, leaner footprint.

If European glass volumes normalise – and cyclical industries with 100-plus-year histories tend to see their cycles turn – the operating leverage in a business like this could work hard in the other direction.

A family-controlled industrial business in a dull, essential industry, trading near multi-year-low earnings while it quietly fixes itself, is exactly the kind of thing the market hates and patient owners like.

Current Price

CHF 18.74 per share

Disclosure

The author is currently not long Vetropack.

Comments

Post a Comment

Popular posts from this blog

Domino's Pizza Group plc (LSE:DOM)

Intro Domino's Pizza Group is the exclusive master franchise holder for Domino's Pizza in the United Kingdom and Ireland. The company doesn't own the Domino's brand itself – it licenses it from the US-based Domino's Pizza Inc – but it does control the entire UK and Irish operation: the supply chain, the digital platform, and the franchise relationships with the local operators who run about 1,400 stores. The UK franchise dates back to 1985, when the first store opened in Luton. The master franchise was acquired in 1993. For a while, management tried to replicate the model abroad – Norway, Sweden, Iceland, Switzerland – but those ventures proved costly and distracting. Between 2019 and 2021, the company exited all its directly operated international markets and refocused entirely on the UK and Ireland. It was the right call. 2025 brought more disruption at the top. CEO Andrew Rennie departed by mutual agreement in November after just two years in the role, repo...
Read more

Tecan Group AG (SWX:TECN)

Intro Tecan Group is a Swiss laboratory automation specialist founded in 1980 by four engineers working out of a home office in Switzerland. Over the past four decades, the company has grown into a global leader in liquid handling, robotic workstations and detection instruments – the kind of equipment that pharma companies, diagnostic labs and university research departments rely on to process samples at scale. If you've had a blood test or a COVID PCR swab, there's a decent chance a Tecan-built machine was involved somewhere along the chain. The company operates in two segments. Life Sciences Business sells instruments and consumables directly to end users. Partnering Business develops and manufactures OEM instruments and components that are then sold by diagnostic and medtech partners under their own brands. The stock has dropped roughly 80% from its September 2021 peak of CHF 602, hammered by a post-pandemic destocking cycle, reduced pharma and biotech R&D spending...
Read more

Rotation Time

Some of the companies discussed on this blog over the years have reached – or come close to – their estimated intrinsic value. With the current market offering a number of compelling new opportunities (more on that soon), it makes sense to rotate out of the winners and redeploy the capital. Two positions to write about: Basler Kantonalbank was first discussed in April 2021. The participation certificates have performed very well since then, reaching the price target. Excluding dividends, the capital gain amounts to roughly 67%. Including the steady dividend payments over the holding period, the total return is even higher. A nice outcome for a quiet, under-the-radar Swiss cantonal bank.   Fresenius SE was highlighted in October 2020 at €34.06. The new management's strategic overhaul – simplifying the group structure, sharpening the focus on Kabi and Helios, and restoring margin discipline – has started to bear fruit, and the market has taken notice. The stock has gained more th...
Read more